Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCOT: Amlenetug in Multiple System Atrophy
NCT06706622Phase 3Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Dec 2024
- Primary completion
- Feb 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of amlenetug in multiple system atrophy (MSA), sponsored by Lundbeck. Started Dec 2024; status: active, not recruiting.
02
Drugs
amlenetug
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT06706622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706622.